Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Octreotide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    120 result(s) found for: Octreotide. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2014-005289-31 Sponsor Protocol Number: LF-PB/14/05 Start Date*: 2015-08-04
    Sponsor Name:CHEMI S.P.A.
    Full Title: A multicentre, double blind, randomized placebo controlled trial to assess the effect of LF-PB on seroma formation in women with breast cancer undergoing Axillary Lymph Node Dissection
    Medical condition: Woman with Breast Cancer Undergoing Axillary Lymph Node Dissection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007153-13 Sponsor Protocol Number: 03-2008 Start Date*: 2009-03-12
    Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY
    Full Title: An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment
    Medical condition: Patients with neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057270 Neuroendocrine carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005825-36 Sponsor Protocol Number: MAFRI-2 Start Date*: 2012-04-03
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Midrodrine, octeotride and albumin for cirrhotic patients with functional renal impairment
    Medical condition: cirrhotic patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000994-22 Sponsor Protocol Number: GADOTATOC-EUS Start Date*: 2011-11-09
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Accuracy and clinical impact of 68-Ga-labeled octreotide analogues PET in diagnosis and staging of duodeno-pancreatic neuroendocrine tumours; proposal of a multicenter, prospective clinical trial
    Medical condition: Patients suspected to be affected by neuroendocrine duodeno-pancreatic neoplasm.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014713 Endocrine neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004075-41 Sponsor Protocol Number: 2020-6941 Start Date*: 2021-02-04
    Sponsor Name:Radboudumc
    Full Title: Effectiveness of Somatostatin Analogues in patients with Gastric antral vascular ectasia and symptomatic gastrointestinal bleeding: SAGAVE-Pilot study
    Medical condition: Gastric Antral Vascular Ectasia (also known as watermelon stomach)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003167-38 Sponsor Protocol Number: NL50643.09r.r4 Start Date*: 2015-04-28
    Sponsor Name:Radboudumc
    Full Title: 68Ga-NODAGA-exendin-4 PET/CT in patients with AHH - a prospective comparative evaluation of preoperative imaging Under the FP7 project Betacure (602812); Personalized diagnosis and treatment of hy...
    Medical condition: Adult endogenous hyperinsulinemic hypoglycemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005852-42 Sponsor Protocol Number: CSMS995BIC03 Start Date*: 2007-04-20
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist i...
    Medical condition: acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005838-37 Sponsor Protocol Number: A-38-52030-214 Start Date*: 2008-05-15
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMI...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DK (Completed) NL (Completed) FI (Completed) LV (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004259-22 Sponsor Protocol Number: ISIS766720-CS2 Start Date*: 2018-06-05
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-000508-39 Sponsor Protocol Number: HM-GCG-201 Start Date*: 2021-10-22
    Sponsor Name:Hanmi Pharm. Co., Ltd.
    Full Title: A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Year...
    Medical condition: Congenital Hyperinsulinism (CHI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10061211 Hyperinsulinism PT
    23.0 100000004850 10083499 Congenital hyperinsulinemic hypoglycemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002513-19 Sponsor Protocol Number: 2011/609-31/1 Start Date*: 2012-10-29
    Sponsor Name:Karolinska University Hospital Solna
    Full Title: 68Ga-DOTATOC-PET/CT for diagnosis of neuroendocrina tumours
    Medical condition: Neuroendocrine tumour
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000398-64 Sponsor Protocol Number: VHIO18001 Start Date*: 2018-06-18
    Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO)
    Full Title: Patterns of uptake of 18F-FDG and 68Ga-DOTA PET in advanced neuroendoctrine tumors
    Medical condition: Gastroenteropancreatic neuroendocrine tumor disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001150-27 Sponsor Protocol Number: 2006/01 Start Date*: 2006-09-11
    Sponsor Name:University Hospital Gent
    Full Title: Sandostatin LAR in prevention of Chemotherapy Induced Diarrhea
    Medical condition: Chemo-Therapy Induced Diarrhea
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004696-11 Sponsor Protocol Number: CSMS995 0802E1 Start Date*: 2005-06-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopath...
    Medical condition: Moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Completed) SE (Completed) DE (Completed) GB (Prematurely Ended) ES (Completed) CZ (Completed) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005552-41 Sponsor Protocol Number: ALADIN Start Date*: 2006-02-20
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study
    Medical condition: Autosomal Dominant Polycystic Kidney Disease ADPKD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038359 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022403-22 Sponsor Protocol Number: CLCI699C2201 Start Date*: 2011-07-04
    Sponsor Name:NOVARTIS FARMA
    Full Title: A proof-of concept, open-label, forced titration, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease
    Medical condition: Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000138-12 Sponsor Protocol Number: ALADIN2 Start Date*: 2011-04-04
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of long-acting somatostatin (Octreotide LAR)therapy on disease progression in patients with Autosoma...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001091-40 Sponsor Protocol Number: 2-47-52030-722 Start Date*: 2004-09-22
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostati...
    Medical condition: Treatment of clinical symptoms of carcinoid syndrome.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 12:53:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA